Journal Papers, Abstracts, and Commentaries
| |
Ligand Binding Pathways and Conformational Transitions of
the HIV Protease.
Miao Y, Huang YM, Walker RC, et
al
Biochemistry.
2018 Feb 2
Abstract
Long-term effectiveness of recommended boosted protease
inhibitor-based antiretroviral therapy in Europe.
Santos JR, Cozzi-Lepri A, Phillips A, et al
HIV Med.
2018 Feb 1.
Abstract
HHV8 and Kaposi's sarcoma: should we really give up
protease inhibitors in all HIV-infected patients?
Philibert P, Chiche L, Caillères S,
et al
AIDS. 2017 Jul 7.
Abstract
Insight
into Binding Mechanisms of Inhibitors MKP56, MKP73, MKP86 and MKP97 to
HIV-1 Protease by Using Molecular Dynamics Simulation
Shi S, Zhang S, Zhang Q.
J Biomol
Struct Dyn. 2017 Mar 9:1-43
Abstract
Strategic use of dual regimens of boosted protease inhibitors plus
maraviroc in poorly adherent subjects in view of long-acting drugs: A
retrospective study.
Capetti AF, Micale M, Carenzi L, et
al
Medicine
(Baltimore).
2017 Feb;96(7):e5728.
Abstract
The choice between a ritonavir-boosted protease
inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based
regimen for initiation of antiretroviral treatment - results from an
observational study in Germany.
Mahlich J, Groß M, Kuhlmann A, Bogner J,
et al
J Pharm Policy Pract.
2016 Dec 30;9:39.
Abstract
Human CaaX Protease ZMPSTE24 Expressed in Yeast:
Structure and Inhibition by HIV Protease Inhibitors.
Clark KM, Jenkins JL, Fedoriw N, Dumont ME.
Protein Sci. 2016 Oct 24. doi: 10.1002/pro.3074.
Paper
FULL-TEXT ARTICLE
HIV Protease Inhibitors Apoptotic Effect in SH-SY5Y Neuronal Cell Line.
Tricarico PM, de Oliveira Franca RF, et al
Cell Physiol Biochem. 2016;39(4):1463-70
Paper
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection.
Ripamonti D.
Evid Based Med. 2016 Aug 26.
Abstract
FULL-TEXT ARTICLE
Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD, Hull M, McVea D, et al
J Int AIDS Soc. 2016 Aug 5;19(1):20978.
Paper
FULL-TEXT ARTICLE
Improved adipose tissue function with initiation of protease inhibitor-only ART.
Maughan RT, Feeney ER, Capel E, etr al
J Antimicrob Chemother. 2016 Aug 11
Paper
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Bonjoch A, Puig J, Pérez-Alvarez N, et al
Medicine (Baltimore). 2016 Aug;95(32):e4507
Abstract
Investigational protease inhibitors as antiretroviral therapies.
Midde NM, Patters BJ, Rao P, et al
Expert Opin Investig Drugs. 2016 Jul 14
Abstract
Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study.
Viciana P, Ocampo A, Hevia H, et al
AIDS Care. 2016 May 3:1-6.
Abstract
FULL-TEXT
LETTER
Protease inhibitors and azolic antifungals in HIV patients with histoplasmosis: a clinical pharmacokinetics perspective
Okumura IM
Braz Jl Infec DApr 16, 2016
Commentary
A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors
Barber TJ, Moyle G, Hill A, et al
HIV Clin Trials. 2016 May;17(3):123-30.
Abstract
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Ghosh AK, Osswald HL, Prato G.
J Med Chem. 2016 Jan 22.
Abstract
Late treatment failures in cerebrospinal fluid in patients on long-term
maintenance ART with ritonavir-boosted protease PI monotherapy.
Kahlert C, Bregenzer A, Gutmann C,
et al
Infection. 2015 Dec 11
Abstract
Differences in the Prediction of Area Under the Curve for
a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment
Using Published Pharmacokinetic Data for Indinavir.
Srinivas NR.
Am J Ther. 2015
Aug 18.
Abstract
FULL-TEXT ARTICLE
Systemic
inflammation and residual viraemia in HIV-positive adults on protease
inhibitor monotherapy: a cross-sectional study.
Arenas-Pinto A, Milinkovic A, Peppa D, et al
BMC Infect Dis.
2015 Mar 21;15(1):138.
Paper
Sildenafil and bosentan plasma concentrations in a human
immunodeficiency virus- infected patient with pulmonary arterial
hypertension treated with ritonavir-boosted protease inhibitor.
Chinello P, Cicalini S, Pichini S,
et al
Infect Dis Rep. 2015
Mar 16;7(1):5822.
Abstract
Low level HIV viremia is more frequent under
protease-inhibitor containing firstline therapy than under NNRTI-regimens
Wiesmann F, Braun P, Knickmann M, Knechten H.
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19828.
Abstract
FULL-TEXT PDF ARTICLE
Inflammatory, procoagulant markers and HIV residual viremia in patients
receiving protease inhibitor monotherapy or triple drug therapy: a
cross-sectional study.
Estébanez M, Stella-Ascariz N, Mingorance J,
BMC
Infect Dis. 2014 Jul
10;14(1):379
Paper
Protease inhibitor monotherapy is not associated with
increased viral replication in lymph nodes.
Vinuesa D, Parra-Ruiz J, Chueca N, et al
AIDS. 2014 May 16.
Abstract
Sequence-Specific Alterations of Epitope Production by
HIV Protease Inhibitors.
Kourjian G, Xu Y, Mondesire-Crump I, et al
J Immunol. 2014 Mar 10.
Abstract
Multi-Step Inhibition against HIV Lifecycle-Underlying the "Magic" of
Protease Inhibitors.
Poveda E.
AIDS Rev. 2014
Jan-Mar;16(1):52.
Abstract
Binary and ternary combinations of anti-HIV protease
inhibitors: effect on gene expression and functional activity of CYP3A4 and
efflux transporters.
Kwatra D, Vadlapudi AD, Vadlapatla RK, et al
Drug Metabol Drug Interact. 2014 Jan
8:1-1
Abstract
Lack of Effect of Doxycycline on Trough Concentrations of Protease
Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected
Patients.
Abgrall S, Le Bel J, Lele N, et al
HIV Clin Trials. 2013
Nov-Dec;14(6):313-8
Abstract
Time to HIV-1 RNA Suppression Below 5 copies/ml During
First-Line Protease Inhibitor-Based Antiretroviral Treatment - Any Impact of
Residual Viremia on Treatment Success?
Ripamonti D, Hill A, Lauthouwers E, van Delft Y, Moecklinghoff C.
AIDS Rev.
2013 Oct-Dec;15(4):230-6.
Abstract
Contribution of Gag and protease to variation in
susceptibility to protease inhibitors between different
strains of subtype B HIV-1.
Sutherland KA, Mbisa JL, Cane PA, et al
J Gen Virol.
2013 Oct 30.
Abstract
Solubility Profiling of HIV Protease
Inhibitors in Human Intestinal Fluids.
Wuyts B, Brouwers J, Mols R, Tack J, et al
J Pharm Sci. 2013
Aug 12.
Abstract
Nucleoside Reverse Transcriptase Inhibitors,
Nonnucleoside Reverse Transcriptase Inhibitors, and Protease
Inhibitors in the Treatment of HIV Infections (AIDS).
De Clercq E.
Adv Pharmacol.
2013;67:317-58.
Abstract
Higher vitamin D levels in HIV-infected
out-patients on treatment with boosted protease inhibitor
monotherapy.
Cervero M, Agud J, Torres R, et al
HIV Med. 2013 Jun 5.
Abstract
Positioning of HIV-protease inhibitors in
clinical practice.
Andreoni M, Perno CF.
Eur Rev Med Pharmacol Sci.
2012 Jan;16(1):10-8.
Abstract |
Complex Drug Interactions of the HIV Protease
Inhibitors 3: Effect of Simultaneous or Staggered
Dosing of
Digoxin and Ritonavir, Nelfinavir, Rifampin or Bupropion.
Kirby BJ, Collier AC, Kharasch ED,
et al
Drug Metab Dispos.
2011 Dec 21.
Abstract
Influence of drug transport proteins on the pharmacokinetics and
drug interactions of
HIV protease inhibitors.
Griffin L, Annaert P, Brouwer KL.
J Pharm Sci.
2011 Jun 22.
.
Abstract
HIV Protease Inhibitors: Effect on the
Opportunistic Protozoan Parasites.
Alfonso Y, Monzote L.
Open Med Chem J.
2011;5:40-50
Abstract
Characterization of HIV-1 from patients with
virological failure to a boosted protease inhibitor regimen.
Lillemark MR, Gerstoft J, Obel N,
et al
J Med Virol.
2011 Mar;83(3):377-383
Abstract
Comparative Molecular Field Analysis of a
Series of Inhibitors of HIV-1 Protease.
Ferreira LG, Leitão A, Montanari CA, Andricopulo AD.
Med Chem.
2011 Jan 11.
Abstract
HIV protease inhibitors: garlic supplements
and first-pass intestinal metabolism impact on the
therapeutic efficacy.
Berginc K, Trdan T, Trontelj J, Kristl A.
Biopharm Drug Dispos.
2010 Oct 26.
Abstract |
Boosted Protease Inhibitor Monotherapy. What Have We Learnt
after Seven Years of Research?
Pulido F, Matarranz M, Rodríguez-Rivera V, et al
AIDS Rev.
2010 Jul-Sep;12(3):127-134
Abstract |
Human immunodeficiency virus protease inhibitors reduce the
growth of human
tumors via a proteasome-independent block of angiogenesis
and matrix
metalloproteinases.
Toschi E, Sgadari C, Malavasi L, et al
Int J Cancer.
2010 Jul 8
Abstract |
Gag Mutations Can Impact Virological Response to Dual Boosted
Protease Inhibitor Combinations in Antiretroviral Naive HIV Infected
Patients (2 IP - ANRS 127 trial).|
Larrouy L, Chazallon C, Landman R,
et al
Antimicrob Agents Chemother.
2010 May 3
Abstract |
Protease inhibitor-based antiretroviral therapy in treatment-naive
HIV-1-infected patients: the evidence behind the options.
Naggie S, Hicks C.
J Antimicrob Chemother. 2010 Apr 23.
Abstract |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by
reducing CD36
and CPT-I fatty acid transporters.
Richmond SR, Carper MJ, Lei X, et al
Biochim Biophys Acta.
2010 Jan 28.
Abstract |
HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired
lipodystrophy in patients on highly active antiretroviral therapy?|
Goulbourne CN, Vaux DJ.
J Biochem Soc Trans. 2010 Feb;38(Pt
1):292-6.
Abstract |
HIV-1 protease inhibitors. A review for clinicians.
Deeks SG, Smith M, Holodniy M, Kahn JO.
JAMA.
1997 Jan 8;277(2):145-53.
Abstract |
HIV Protease Inhibitors Induce ER Stress and Disrupt Barrier
Integrity in Intestinal Epithelial Cells.
Wu X, Sun L, Zha W, Studer E, et al
Gastroenterology.
2009 Sep 1.
Abstract |
HIV protease inhibitors: recent clinical trials and
recommendations on use.
Fernández-Montero JV, Barreiro P, Soriano V.
Expert Opin Pharmacother.
2009 Jul;10(10):1615-29.
Abstract |
Regulatory issues in developing new HIV protease inhibitors:
risks and benefits.
Struble KA, Chan-Tack KM, Soon GG.
Curr Opin HIV AIDS. 2008
Nov;3(6):676-80.
Abstract |
Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in
Subjects Receiving HAART
During Acute or Early HIV Infection.
Ernstrom KB, Little SJ, Routy JP, et al
J Acquir Immune Defic Syndr.
2009 Feb 3.
Abstract
|
Tolerability and Safety of HIV Protease Inhibitors in Adults.
Sax PE, Kumar P.
J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-1124
Abstract
|
Simplification of antiretroviral treatment--how to sustain success, reduce
toxicity
and
ensure
adherence avoiding PI use.
Barreiro P, Garcia-Benayas T, Soriano V, Gallant
J.
AIDS Rev 2002 Oct-Dec;4(4):233-41
Abstract
Therapeutic drug monitoring of HIV-protease inhibitors to assess
noncompliance.
Hugen PW, Burger DM, Aarnoutse RE,et al|
Ther Drug Monit 2002 Oct;24(5):579-87
Abstract
Factors associated with mortality in human immunodeficiency virus type
1-infected
adults initiating protease inhibitor-containing therapy: role of education
level and of
early transaminase
level elevation (APROCO-ANRS EP11 study).
The Antiproteases
Cohorte Agence Nationale de Recherches sur
le SIDA EP 11 study.Lewden C, Raffi F, Cuzin L, et al
J Infect Dis 2002 Sep
1;186(5):710-4
Abstract
|
|
|
Drugs Main Page
